Allogene Therapeutics/ALLO

$2.52

-
-
1D1W1MYTD1YMAX

About Allogene Therapeutics

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.

Ticker

ALLO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

David Chang

Employees

232

Headquarters

South san francisco, United States

ALLO Metrics

BasicAdvanced
$525M
Market cap
-
P/E ratio
-$1.78
EPS
0.86
Beta
-
Dividend rate
$525M
0.85722
$6.05
$2.23
2.4M
12.797
-43.85%
-55.48%
-47.04%
6,035.95
0.931
1.138
-30.4%
29.01%

What the Analysts think about ALLO

Analyst Ratings

Majority rating from 17 analysts.
Buy

Price Targets

Average projection from 11 analysts.
358.33% upside
High $35.00
Low $4.50
$2.52
Current price
$11.55
Average price target

ALLO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$65M
-80.13%
Profit margin
0%
NaN%

ALLO Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.17%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.53
-$0.37
-$0.51
-$0.38
-
Expected
-$0.59
-$0.52
-$0.45
-$0.41
-$0.35
Surprise
-10.01%
-28.78%
13.55%
-7.17%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Allogene Therapeutics stock?

Allogene Therapeutics (ALLO) has a market cap of $525M as of May 28, 2024.

What is the P/E ratio for Allogene Therapeutics stock?

The price to earnings (P/E) ratio for Allogene Therapeutics (ALLO) stock is 0 as of May 28, 2024.

Does Allogene Therapeutics stock pay dividends?

No, Allogene Therapeutics (ALLO) stock does not pay dividends to its shareholders as of May 28, 2024.

When is the next Allogene Therapeutics dividend payment date?

Allogene Therapeutics (ALLO) stock does not pay dividends to its shareholders.

What is the beta indicator for Allogene Therapeutics?

Allogene Therapeutics (ALLO) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Allogene Therapeutics stock price target?

The target price for Allogene Therapeutics (ALLO) stock is $11.55, which is 358.33% above the current price of $2.52. This is an average based on projections from 11 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Allogene Therapeutics stock

Buy or sell Allogene Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing